NCT00412594View on ClinicalTrials.gov

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 10, 2004

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia
Interventions
DRUG

Cladribine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER